Generic medicine

Coagulation Factor VIIa [Eptacog Alfa]: Brands, Price & Uses in Bangladesh

Coagulation Factor VIIa [Eptacog Alfa] is a recombinant activated human coagulation factor VII used for hemostatic management under specialist supervision.

Forms:IV Injection

About Coagulation Factor VIIa [Eptacog Alfa]

Indications of Coagulation Factor VIIa [Eptacog Alfa]

Coagulation Factor VIIa [Eptacog Alfa] is a recombinant activated human coagulation factor VII used for hemostatic management under specialist supervision. Indications are classified below by strength of evidence.

Established / FDA-approved uses

  • Treatment of bleeding episodes in patients with congenital hemophilia A or B with inhibitors to factor VIII or IX.
  • Prevention of bleeding during surgical or other invasive procedures in patients with congenital hemophilia A or B with inhibitors.
  • Treatment of bleeding episodes and perioperative (surgical) management in patients with acquired hemophilia (autoantibodies to factor VIII).
  • Treatment of bleeding episodes and perioperative management in patients with congenital Factor VII deficiency.
  • Treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia who are refractory to platelet transfusions, with or without antibodies to platelets.

Off-label / adjunct use (not routinely recommended)

  • Uncontrolled or life-threatening hemorrhage in other settings (e.g. trauma, intracranial hemorrhage, cardiac surgery, liver disease) has been used off-label in some centers, but evidence is limited and use outside approved indications carries increased thrombotic risk; this use is not FDA-approved and should occur only under specialist direction in a hospital setting.

In all cases, Coagulation Factor VIIa [Eptacog Alfa] should be initiated and dosed only by, or in close consultation with, a hematologist experienced in bleeding disorder management, ideally coordinated with a hemophilia treatment center.

Dosage & Administration of Coagulation Factor VIIa [Eptacog Alfa]

Dosing of Coagulation Factor VIIa [Eptacog Alfa] is individualized by indication, body weight, and severity/site of bleeding, and must be directed by a hematology specialist. Representative dosing is summarized below; refer to the approved product labeling and treating physician's protocol for the specific product used.

IndicationDoseInterval
Hemophilia A/B with inhibitors (bleeding episodes/surgery)90 mcg/kg IV bolusEvery 2 hours until hemostasis achieved, then interval may be increased
Acquired hemophilia70-90 mcg/kg IV bolusEvery 2-3 hours until hemostasis
Congenital Factor VII deficiency15-30 mcg/kg IV bolusEvery 4-6 hours until hemostasis
Glanzmann's thrombasthenia (platelet-refractory)90 mcg/kg IV bolusEvery 2 hours, minimum of 3 doses

Administered as a slow intravenous bolus injection over approximately 2-5 minutes; see Administration and Reconstitution for preparation and injection technique, and Duration of Treatment for guidance on tapering.

Side Effects of Coagulation Factor VIIa [Eptacog Alfa]

Because Coagulation Factor VIIa [Eptacog Alfa] is used in seriously ill patients with bleeding disorders, distinguishing drug-related effects from the underlying condition can be difficult. Reported adverse effects include:

Common

  • Fever
  • Injection/infusion site reactions
  • Headache
  • Hypertension or hypotension
  • Nausea, vomiting
  • Pain (including at the surgical or bleeding site)

Serious (uncommon but clinically important)

  • Arterial and venous thromboembolic events (e.g. myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, intra-abdominal thrombosis) - see Precautions and Warnings for full detail.
  • Hypersensitivity/allergic reactions, including rare anaphylaxis.
  • Development of antibodies to factor VII (rare) or inhibitory antibodies in congenital Factor VII deficiency.

Contraindications of Coagulation Factor VIIa [Eptacog Alfa]

Coagulation Factor VIIa [Eptacog Alfa] is contraindicated in patients with known hypersensitivity to eptacog alfa or to any other component of the product, including possible trace residual proteins from the manufacturing process (such as mouse, hamster, or bovine protein, depending on the specific product) - hypersensitivity should be verified against the manufacturing process of the specific product dispensed.

Frequently Asked Questions about Coagulation Factor VIIa [Eptacog Alfa]

What is Coagulation Factor VIIa [Eptacog Alfa] used for?

Coagulation Factor VIIa [Eptacog Alfa] is a recombinant activated coagulation factor used to control and prevent bleeding episodes, including during surgery, in patients with hemophilia A or B who have developed inhibitors, in acquired hemophilia, in congenital Factor VII deficiency, and in Glanzmann's thrombasthenia that does not respond to platelet transfusions. It is used only under the direction of a hematology specialist.

How is Coagulation Factor VIIa [Eptacog Alfa] given?

Coagulation Factor VIIa [Eptacog Alfa] is given as a slow intravenous bolus injection, usually over 2-5 minutes, after being reconstituted from a powder with the diluent supplied with the product. It is administered in a hospital or specialist clinical setting, repeated at intervals directed by the treating physician until bleeding is controlled.

What is the most serious risk with Coagulation Factor VIIa [Eptacog Alfa]?

The most serious risk is thrombosis - Coagulation Factor VIIa [Eptacog Alfa] carries a boxed warning for serious, sometimes fatal, arterial and venous blood clots, particularly when used outside approved indications/dosing or in patients with underlying risk factors such as atherosclerotic disease, severe liver disease, or DIC. Patients are monitored closely for symptoms such as chest pain, leg swelling, or sudden weakness.

Can Coagulation Factor VIIa [Eptacog Alfa] be used in children?

Yes. Coagulation Factor VIIa [Eptacog Alfa] is used in pediatric patients, including neonates, for its approved indications, using the same weight-based dosing as adults, though younger children may need shorter dosing intervals. Use outside these established indications is not established as safe and effective in children and should only occur under specialist supervision.

Is Coagulation Factor VIIa [Eptacog Alfa] safe during pregnancy?

There is limited data on Coagulation Factor VIIa [Eptacog Alfa] in pregnancy. It should be used only if clearly needed, with the potential benefit to the mother weighed against any potential risk to the fetus, and only after consultation with a physician.

What should I do if a dose of Coagulation Factor VIIa [Eptacog Alfa] is missed or a bleed is not controlled?

Coagulation Factor VIIa [Eptacog Alfa] is administered under direct medical supervision in a hospital setting, so missed doses are managed by the treating team. If bleeding is not controlled after the recommended dosing, contact the treating hematology specialist immediately for reassessment rather than self-adjusting the dose.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles